Multimarker Panels in Sepsis

Critical Care Clinics

Volumn 27, Issue 2, 2011, Pages 391-405

  Casserly, Brian ^a   Read, Richard ^b   Levy, Mitchell M ^b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Biomarkers; Multimarker panels; Sepsis; Statistics; Systemic inflammatory response syndrome

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3A; ELASTASE; EOTAXIN; FAS ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INHIBITING FACTOR; MATRILYSIN; MATRIX METALLOPROTEINASE; PROCALCITONIN; PROTEIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; STROMELYSIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANTIBIOTIC THERAPY; APACHE; BACTERIUM CULTURE; BLOOD CLOTTING DISORDER; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; INNATE IMMUNITY; INTENSIVE CARE; MODEL; NEUTROPHIL COUNT; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REPRODUCIBILITY; REVIEW; SAMPLE SIZE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; STATISTICAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CRITICAL CARE; HUMANS; SEPSIS; STATISTICS AS TOPIC;

EID: 79953000353     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.12.011     Document Type: Review

References (93)

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89.
2. Allen L.A. Use of multiple biomarkers in heart failure. Curr Cardiol Rep 2010, 12:230.
3. LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res 2005, 4:1053.
4. Marshall J.C., Reinhart K. Biomarkers of sepsis. Crit Care Med 2009, 37:2290.
5. Bozza F.A., Salluh J.I., Japiassu A.M., et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007, 11:R49.
6. Hartemink K.J., Groeneveld A.B., de Groot M.C., et al. Alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock. Crit Care Med 2001, 29:80.
7. Parikh C.R., Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008, 36:S159.
8. Robin X., Turck N., Hainard A., et al. Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics?. Expert Rev Proteomics 2009, 6:675.
9. Khan S.S., Smith M.S., Reda D., et al. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 2004, 61:35.
10. Azuaje F., Devaux Y., Wagner D. Computational biology for cardiovascular biomarker discovery. Brief Bioinform 2009, 10:367.
11. Schiess R., Wollscheid B., Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009, 3:33.
12. McIntosh M.W., Pepe M.S. Combining several screening tests: optimality of the risk score. Biometrics 2002, 58:657.
13. Pepe M.S., Thompson M.L. Combining diagnostic test results to increase accuracy. Biostatistics 2000, 1:123.
14. Marshall J.C. Sepsis: rethinking the approach to clinical research. J Leukoc Biol 2008, 83:471.
15. Allen L.A., Felker G.M. Multi-marker strategies in heart failure: clinical and statistical approaches. Heart Fail Rev 2010, 15:343.
16. Wishart D.S. Computational approaches to metabolomics. Methods Mol Biol 2010, 593:283.
17. Chau C.H., Rixe O., McLeod H., et al. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008, 14:5967.
18. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005, 5:142.
19. Feng Z., Prentice R., Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004, 5:709.
20. Feng Z., Yasui Y. Statistical considerations in combining biomarkers for disease classification. Dis Markers 2004, 20:45.
21. Carrigan S.D., Scott G., Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem 2004, 50:1301.
22. Russell J.A. Management of sepsis. N Engl J Med 2006, 355:1699.
23. Catenacci M.H., King K. Severe sepsis and septic shock: improving outcomes in the emergency department. Emerg Med Clin North Am 2008, 26:603.
24. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644.
25. Marshall J.C., Vincent J.L., Fink M.P., et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable. Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003, 31:1560.
26. Brun-Buisson C., Doyon F., Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996, 154:617.
27. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274:968.
28. Suau A., Bonnet R., Sutren M., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999, 65:4799.
29. Weng L., Rubin E.M., Bristow J. Application of sequence-based methods in human microbial ecology. Genome Res 2006, 16:316.
30. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462.
31. Claus R.A., Otto G.P., Deigner H.P., et al. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. Curr Mol Med 2010, 10:227.
32. Assicot M., Gendrel D., Carsin H., et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515.
33. Castelli G.P., Pognani C., Meisner M., et al. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004, 8:R234.
34. Dahaba A.A., Hagara B., Fall A., et al. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006, 97:503.
35. Harbarth S., Holeckova K., Froidevaux C., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396.
36. Jensen J.U., Heslet L., Jensen T.H., et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006, 34:2596.
37. Muller B., Becker K.L., Schachinger H., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977.
38. Nobre V., Harbarth S., Graf J.D., et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177:498.
39. Lehmann L.E., Hunfeld K.P., Emrich T., et al. A multiplex real-time PCR assay for rapid detection and differentiation of 25 bacterial and fungal pathogens from whole blood samples. Med Microbiol Immunol 2008, 197:313.
40. Mussap M., Molinari M.P., Senno E., et al. New diagnostic tools for neonatal sepsis: the role of a real-time polymerase chain reaction for the early detection and identification of bacterial and fungal species in blood samples. J Chemother 2007, 19(Suppl 2):31.
41. Leon A.C. Implications of clinical trial design on sample size requirements. Schizophr Bull 2008, 34:664.
42. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 1982, 14:473.
43. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004, 4:309.
44. Ghosh D., Poisson L.M. " Omics" data and levels of evidence for biomarker discovery. Genomics 2009, 93:13.
45. Mehta T., Tanik M., Allison D.B. Towards sound epistemological foundations of statistical methods for high-dimensional biology. Nat Genet 2004, 36:943.
46. Lijmer J.G., Mol B.W., Heisterkamp S., et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999, 282:1061.
47. Soreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol 2009, 62:1.
48. Simon R. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 2008, 44:2707.
49. Vitzthum F., Behrens F., Anderson N.L., et al. Proteomics: from basic research to diagnostic application. A review of requirements & needs. J Proteome Res 2005, 4:1086.
50. Williams F.M. Biomarkers: in combination they may do better. Arthritis Res Ther 2009, 11:130.
51. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054.
52. Lassere M.N. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008, 17:303.
53. Ambroise C., McLachlan G.J. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A 2002, 99:6562.
54. Molenberghs G., Burzykowski T., Alonso A., et al. A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res 2004, 13:177.
55. Pepe M.S., Feng Z., Janes H., et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008, 100:1432.
56. Smit S., van Breemen M.J., Hoefsloot H.C., et al. Assessing the statistical validity of proteomics based biomarkers. Anal Chim Acta 2007, 592:210.
57. Taylor J.M., Ankerst D.P., Andridge R.R. Validation of biomarker-based risk prediction models. Clin Cancer Res 2008, 14:5977.
58. Zervakis M., Blazadonakis M.E., Tsiliki G., et al. Outcome prediction based on microarray analysis: a critical perspective on methods. BMC Bioinformatics 2009, 10:53.
59. Boulesteix A.L., Strobl C. Optimal classifier selection and negative bias in error rate estimation: an empirical study on high-dimensional prediction. BMC Med Res Methodol 2009, 9:85.
60. Wiemer J.C., Prokudin A. Bioinformatics in proteomics: application, terminology, and pitfalls. Pathol Res Pract 2004, 200:173.
61. Shariat S.F., Lotan Y., Vickers A., et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010, 28:389.
62. Subtil F., Rabilloud M.A. Bayesian method to estimate the optimal threshold of a longitudinal biomarker. Biom J 2010, 52:333.
63. Scotch M., Duggal M., Brandt C., et al. Use of statistical analysis in the biomedical informatics literature. J Am Med Inform Assoc 2010, 17:3.
64. Omenn G.S. Strategies for plasma proteomic profiling of cancers. Proteomics 2006, 6:5662.
65. Smit S., Hoefsloot H.C., Smilde A.K. Statistical data processing in clinical proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 866:77.
66. Eldridge S., Ashby D., Bennett C., et al. Internal and external validity of cluster randomised trials: systematic review of recent trials. BMJ 2008, 336:876.
67. James Hung H.M., Wang S.J. Challenges to multiple testing in clinical trials. Biom J 2010, 52:747-756.
68. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007, 115:928.
69. Sylvester R.J. Combining a molecular profile with a clinical and pathological profile: biostatistical considerations. Scand J Urol Nephrol Suppl 2008, 218:185.
70. Levinson S.S. Weak associations between prognostic biomarkers and disease in preliminary studies illustrates the breach between statistical significance and diagnostic discrimination. Clin Chim Acta 2010, 411:467.
71. Baker S.G. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 2003, 95:511.
72. Thompson M.L., Zucchini W. On the statistical analysis of ROC curves. Stat Med 1989, 8:1277.
73. Kofoed K., Eugen-Olsen J., Petersen J., et al. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008, 27:375.
74. Kofoed K., Schneider U.V., Scheel T., et al. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 2006, 52:1284.
75. Kofoed K., Andersen O., Kronborg G., et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007, 11:R38.
76. Selberg O., Hecker H., Martin M., et al. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000, 28:2793.
77. Punyadeera C., Schneider E.M., Schaffer D., et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J Emerg Trauma Shock 2010, 3:26.
78. Dhainault J.F., Shorr A.F., Macias W.L., et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005, 33:341.
79. Shapiro N.I., Trzeciak S., Hollander J.E., et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009, 37:96.
80. Ginsburg G.S., Seo D., Frazier C. Microarrays coming of age in cardiovascular medicine: standards, predictions, and biology. J Am Coll Cardiol 2006, 48:1618.
81. Gillette M.A., Mani D.R., Carr S.A. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005, 4:1143.
82. Zhang Z., Chan D.W. Cancer proteomics: in pursuit of " true" biomarker discovery. Cancer Epidemiol Biomarkers Prev 2005, 14:2283.
83. Gerszten R.E., Accurso F., Bernard G.R., et al. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol 2008, 295:L16.
84. Wang P., Whiteaker J.R., Paulovich A.G. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther 2009, 8:1083.
85. Foteinou P.T., Calvano S.E., Lowry S.F., et al. Translational potential of systems-based models of inflammation. Clin Transl Sci 2009, 2:85.
86. Laubenbacher R., Hower V., Jarrah A., et al. A systems biology view of cancer. Biochim Biophys Acta 2009, 1796:129.
87. Hurst R.E. Does the biomarker search paradigm need re-booting?. BMC Urol 2009, 9:1.
88. Kohl P., Crampin E.J., Quinn T.A., et al. Systems biology: an approach. Clin Pharmacol Ther 2010, 88:25.
89. Volonte C., D'Ambrosi N., Amadio S. Protein cooperation: from neurons to networks. Prog Neurobiol 2008, 86:61.
90. Calvano S.E., Xiao W., Richards D.R., et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032.
91. Friend S.H. The need for precompetitive integrative bionetwork disease model building. Clin Pharmacol Ther 2010, 87:536.
92. Azuaje F., Devaux Y., Wagner D.R. Coordinated modular functionality and prognostic potential of a heart failure biomarker-driven interaction network. BMC Syst Biol 2010, 4:60.
93. Fogel G.B. Computational intelligence approaches for pattern discovery in biological systems. Brief Bioinform 2008, 9:307.